Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

被引：32

作者：

Diefenbach, Catherine S. ^{[1
]}

Hong, Fangxin ^{[2
]}

David, Kevin A. ^{[3
]}

Cohen, Jonathon ^{[4
]}

Robertson, Michael ^{[5
]}

Advani, Ranjana ^{[6
]}

Palmisiano, Neil D. ^{[7
]}

Ambinder, Richard F. ^{[8
]}

Kahl, Brad S. ^{[9
]}

Ansell, Stephen ^{[10
]}

机构：

[1] NYU Sch Med, NYU Perlmutter Canc Ctr, New York, NY USA

[2] Dana Farber Canc Inst, ECOG ACRIN Biostatist Ctr, Boston, MA USA

[3] Northwestern Univ Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL USA

[4] Emory Univ, Atlanta, GA USA

[5] Indiana Univ Sch Med, Indianapolis, IN USA

[6] Stanford Canc Inst, Stanford, CA USA

[7] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA

[8] Johns Hopkins Med Inst, Div Hematol Malignancies, SKCCC, Baltimore, MD USA

[9] Washington Univ, St Louis, MO USA

[10] Mayo Clin, Rochester, MN USA

来源：

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1182/blood.V128.22.1106.1106

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1106

引用

页数：6